Friday, 23 February 2018

Aeon Global Health partners with Sabal Therapeutics

18 January 2018 | News

Aeon Global Health declared marketing and sales agreement for Trusted Branded Pharmaceutical Company to market non-opiate pain management drug with its drug monitoring services to physicians and healthcare facilities on nationwide basis

Aeon Global Health, the operating arm of Authentidate Holding Corp., a growth-oriented provider of personalized, clinically actionable medical informatics and telemedicine.

The company announced that it has agreed with Sabal Therapeutics, LLC to be the primary laboratory marketer of Naprosyn, the branded naproxen oral suspension USP.

Under the agreement, Aeon will become the exclusive clinical laboratory marketing representative of Sabal and will market the drug alongside of its industry-leading drug monitoring service.

Thus can providing physicians with an integrated, non-opiate solution for pain management. 

Because Naprosyn is dispensed in a liquid form; healthcare professionals can more accurately prescribe and adjust the dosage based on individual patient needs.

Specially for patients whose weight, medical condition or pain severities appropriately permit flexible dosing versus the fixed dosage of tablets.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account





Survey Box

Will the world's largest public healthcare scheme work?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls